Major Trial Compares Two Kidney Treatment Approaches for Critically Ill Patients

The New England Journal of Medicine posted findings from the ICRAKI trial — a study comparing two established methods of renal-replacement therapy (dialysis) used when the kidneys suddenly stop working, a condition known as acute kidney injury. The trial directly addresses one of intensive care medicine’s long-standing clinical debates.

Acute kidney injury is a rapid loss of kidney function, often seen in critically ill hospital patients. When it becomes severe enough to require treatment, clinicians have two main options: continuous renal-replacement therapy, which filters the blood slowly and steadily around the clock, or intermittent renal-replacement therapy, which does so in shorter, more intensive sessions — typically three to four hours at a time.

The question of which approach produces better patient outcomes has been debated in nephrology (the branch of medicine dealing with kidney disease) for decades. Both methods are widely used in intensive care units across the NHS, and the choice has often come down to local practice, available equipment, or individual clinical judgement rather than definitive trial evidence.

Meanwhile, the NEJM also published an accompanying editorial — *Continuous or Intermittent Renal-Replacement Therapy — What Is the Question?* — suggesting the findings prompt further scrutiny of how the clinical question itself is framed.

Full details of the trial’s results, patient population, and primary outcomes are available in the published article. Readers with concerns about kidney health should speak to their GP or call NHS 111.